Biopharma Daily Stock Updates - 02/09/21

$XBI $171.86 -1% 📉


$HTBX +50% Positive interim survival data from ongoing HS-110 ph 2 NSCLC trial. source

$RMTI +30% Commercial launch in US of Triferic® AVNU for replacement of iron and maintenance of hemoglobin in patients on hemodialysis. source

$ORTX +14% Positive interim data for OTL-203 in MPS-IH. source

$ELOX +9% Publication of scientific manuscript on ELX-02 in the Journal of Cystic Fibrosis. source

$KALV +114% Phase 2 positive results across all endpoints for KVD900 as an oral on-demand treatment for HAE attacks. source

$IPHA +1% Innate Pharma advances lacutamab clinical development program. source

$AMRN +1% Update on VASCEPA regulatory process in mainland China and Hong Kong. source

$AGEN -1% New clinical response data for AGEN1181. source


$KALV +114% Offering

$ACET -2% Offering

$CDAK -9% Offering

$ONCR +1% Offering